IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.
Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, Anguita E, Islam ABMMK, Romero-Moya D, Prieto C, Gutierrez-Agüera F, Bejarano-Garcia JA, Perez-Simon JA, Costales P, Rovira M, Marín P, Menendez S, Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menendez P.
Lopez-Millan B, et al. Among authors: menendez p, menendez s.
Oncoimmunology. 2018 Jul 26;7(9):e1477460. doi: 10.1080/2162402X.2018.1477460. eCollection 2018.
Oncoimmunology. 2018.
PMID: 30228947
Free PMC article.